Ma Songjiang 4
4 · GYRE THERAPEUTICS, INC. · Filed Mar 21, 2025
Insider Transaction Report
Form 4
Ma Songjiang
DirectorPresident
Transactions
- Sale
Common Stock
2025-03-19$10.13/sh−2,000$20,260→ 2,827,018 total(indirect: By Spouse) - Sale
Common Stock
2025-03-20$10.09/sh−2,000$20,180→ 2,825,018 total(indirect: By Spouse)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.